Clinical Trials List
2023-12-15 - 2028-06-30
Phase III
Recruiting5
ICD-10E85.0
Non-neuropathic heredofamilial amyloidosis
ICD-10E85.1
Neuropathic heredofamilial amyloidosis
ICD-10E85.2
Heredofamilial amyloidosis, unspecified
ICD-10E85.3
Secondary systemic amyloidosis
ICD-10E85.4
Organ-limited amyloidosis
ICD-10E85.8
Other amyloidosis
ICD-10E85.9
Amyloidosis, unspecified
ICD-9277.3
Amyloidosis
-
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/09/11
Investigators and Locations
Co-Principal Investigator
- 王維庭 無
- Shih-Hsien Sung 無
- Yi-Chun Lee Division of Neurology
- Kon-Ping Lin 無
- 郭泠 無
- 黃偉銘 無
- 廖若男 無
- Yi-Chu Liao Division of Neurology
- Yo-Tsen Liu Division of Neurology
- 季康揚 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王奇彥 無
- 周政達 無
- WEI-WEN LIN 無
- 黃祺耀 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林恆旭 Division of Cardiovascular Diseases
- 莊文博 Division of Cardiovascular Diseases
- 許榮城 Division of Neurology
- 曾炳憲 Division of Cardiovascular Diseases
- YEN-HSIANG HUANG Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 呂尚謁 無
- 林晏年 無
- Yuh-Cherng Guo 無
- 董承昌 Division of Cardiovascular Diseases
- 鍾偉信 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
40 participants
-
Global
1000 participants
